Go to content
UR Home

MGMT methylation status: the advent of stratified therapy in glioblastoma?

Hau, Peter, Stupp, Roger and Hegi, Monika E. (2007) MGMT methylation status: the advent of stratified therapy in glioblastoma? Disease markers 23 (1-2), pp. 97-104.

Full text not available from this repository.

at PubMed


Abstract

Glioblastomas are the most malignant gliomas with median survival times of only 15 months despite modern therapies. All standard treatments are palliative. Pathogenetic factors are diverse, hence, stratified treatment plans are warranted considering the molecular heterogeneity among these tumors. However, most patients are treated with "one fits all" standard therapies, many of them with minor ...

plus


Export bibliographical data



Item type:Article
Date:2007
Institutions:Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT)
Identification Number:
ValueType
17325429PubMed ID
Classification:
NotationType
AnimalsMESH
DNA Modification Methylases/metabolismMESH
DNA Repair Enzymes/metabolismMESH
Drug Resistance, Neoplasm/physiologyMESH
Glioblastoma/metabolismMESH
HumansMESH
MethylationMESH
Tumor Suppressor Proteins/metabolismMESH
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Status:Published
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Unknown
Item ID:29304
Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons